... Validation of the Euro-pean Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breastcancer patients. Eur J Cancer 1998, ... in breast cancer – taking stock. Journal of the National Cancer Institute2003, 95(4):263-281.46. Montazeri A: Health-related quality of life in breast cancer patients: a bibliographic review of ... interventions for breast cancer survivors [9-18]. Given the high prevalence of breastcancer and budget constraints in health care, it isalso important to understand the impact of alternativestrategies...
... nanocapsule form. This observation was consistent with a previous report [48] related to a nanoparticulate form of another anticancer drug (doxorubicin) tested on a different breastcancer cell ... agent used in the treatment of various typesof cancers, including metastatic breast, ovarian, prostate, advanced non-small-cell lung, head/neck, and advanced gastric cancers by inhibiting the ... side effects [22]. One of the reasons could be ascribed to the composition of the formulation and the poor control of the drug release rate. Therefore, the development of compatible polymer-based...
... the for- mer, the most used in Europe forbreastcancer are theEuropean Organization for Research and Treatment of Cancer Core Cancer Quality Life Questionnaire(EORTC QLQ-C30) and its breast- cancer- speci ... methodological quality of studies was assessed.Results: Spain ranked midway in the European Union in terms of the number of studies conducted on the HRQL of breastcancer patients. Of the total of 133 papers ... EuropeanOrganization for Research and Treatment of Cancer; EORTC QLQ-BR23:European Organization for Research and Treatment ofCancer Quality LifeQuestionnaire BreastCancer Specific Module;...
... J Cancer 1991, 64:1133-1138.12. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 539 have been followed up for 15 years. Br J Cancer ... JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987, 56:489-492.14. Lonn U, Lonn S, Nilsson B, Stenkvist B: Breast cancer: prognosticsignificance of c-erb-B2 and ... Serum levels of IL-6 correlates well with the extent of tumor invasion, LN metastasis, distantmetastasis and TNM staging thus enveloping all aspects ofbreast cancer. Introduction Breast cancer is...
... of immunocytochemically localizedestrogen receptors in human breast cancer. Cancer Res 1990,5012:3545-3550.9. British Breast Group: Assessment of response to treatment in advanced breast cancer. ... 9:101http://www.wjso.com/content/9/1/101Page 2 of 4 RESEARC H Open AccessClinical relevance of “withdrawal therapy” as aform of hormonal manipulation forbreast cancer Amit Agrawal*, John FR Robertson ... Duration of treat-ment (DoT) is the duration of therapy in months of all patients (regardless of the type of response) and includ-ing patient still on treatmentResultsSeventeen patients with...
... type of organization for the treatment ofbreast cancer. Thischange will be driven not much from “ mandatory”requirements, but by the willingness of more sophisti-cated breastcancerpatients ... type of mastectomy forbreastcancer treatment. Breast Cancer Res Treat 2006, 96:47-51.102. Gulben K, Yildirim E, Berberoglu U: Prediction of occult nipple-areolacomplex involvement in breastcancer ... R,Taylor C, Wang Y: Early BreastCancer Trialists’ Collaborative Group(EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breastcancer on local recurrence...
... Agency for Researchon Cancer, Lyon, France 1996, 66:253-365.11. Swerdlow AJ, Jones ME: Tamoxifen treatment forbreastcancer and risk of endometrial cancer: a case-control study. J Natl Cancer ... feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989, 60(1):126-31.4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM:Endometrial cancer in tamoxifen-treated ... eutic agent has led to its prophy-lactic use in the prevention ofbreastcancer in healthywomen at high risk of developing breastcancer and ithas also shown efficacy in this regard [9]. Despite...
... predictor of malignancy.Conclusion: Age ( 50) at the time of biopsy is an independent predictive factor forbreast cancer at surgical excision in patients with diagnosed ADH at CNB. Forpatients ... factor forbreastcancer at surgical excisionin patients with diagnosed ADH at CNB. Identification of patients with ADH diagnosed by CNB who can be sparedsurgical excision is an area of active ... performed on sus-picious breast lesions at the Seoul St. Mary's Hospital. Atotal of 69 CNBs led to a diagnosis of ADH, and 45 patients underwent follow-up surgical excision. Sevenpatients...
... severity of acute breastcancer ther-apy-related morbidity is very limited. Breast- conserving therapy (BCT) is the accepted stan-dard treatment for early-stage breastcancer (BC) andconsists of ... treatment for BC should be performed inelderly women.IntroductionWith the aging of th e population, more older womenare being diagnosed with breast cancer. Over 40% of allnewly diagnosed breastcancer ... 5:103http://www.ro-journal.com/content/5/1/103Page 7 of 9 RESEARC H Open AccessIs standard breast- conserving therapy (BCT) inelderly breastcancerpatients justified? Aprospective measurement of acute toxicityaccording...
... individual risks forbreastcancer 60-85% and may be identified in 5-10% of all breastcancer cases.28 Personal history of noninvasive breastcancer or previous abnormal breast biopsy containing ... risk forbreastcancer mortality of 0.85 (95% CrI, 0.75-0.96) for women randomly assigned to screening, and a number needed to invite for screening to prevent one breastcancer death of 1,904 ... study of 485 women who received CBE within one year prior to breastcancer diagnosis and within 15 years ofbreastcancer death revealed that CBE failed to detect breastcancer in 4 out of 5...